Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03324529 · ClinicalTrials.gov registry record · NA
Autonomic Modulation in Takotsubo Syndrome
A NA study of Takotsubo Syndrome, sponsored by NYU Langone Health.
- Active
- Registry status
- NA
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT03324529 is a NA study of Takotsubo Syndrome that is active but no longer recruiting, run by NYU Langone Health. The registered enrollment target is 24 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03324529, a NA study of Takotsubo Syndrome, is active but no longer recruiting, sponsored by NYU Langone Health.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a minimal risk case-controlled single arm intervention study, including 10 patients with a prior history of takotsubo and 10-age and sex matched healthy controls. Subjects will undergo in laboratory testing to measure autonomic function. They will then undergo a 15-week program of device-guided breathing with remote measures of autonomic function obtained at home. Analysis will determine the reproducibility of home autonomic measures and the provide preliminary data to determine the efficacy of device-guided breathing on autonomic measures and quality of life in patients with takotsubo.
Conditions Studied
Interventions
- DEVICE Tako Breath
Study Locations (1)
New York
- New York University School of Medicine - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2021-10-01 |
| Est. Completion | 2027-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03324529
The ClinicalTrials.gov registry entry for NCT03324529 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Takotsubo Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Tako Breath is the first listed.
NCT03324529 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03324529 about?
NCT03324529 is a clinical study titled "Autonomic Modulation in Takotsubo Syndrome". This is a minimal risk case-controlled single arm intervention study, including 10 patients with a prior history of takotsubo and 10-age and sex matched healthy controls. Subjects will undergo in laboratory testing to measure autonomic function. They will then undergo a 15-week program of device-gui...
What is the current status of trial NCT03324529?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 24 participants. The study started on 2021-10-01. Estimated completion is 2027-06.
What conditions does trial NCT03324529 study?
This clinical trial studies the following conditions: Takotsubo Syndrome.
What interventions are being tested in trial NCT03324529?
The interventions under investigation include: Tako Breath (DEVICE).
Who is sponsoring clinical trial NCT03324529?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03324529 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.